Cargando…
Molecular Markers of Telomerase Complex for Patients with Pituitary Adenoma
Pituitary adenoma (PA) is the most common benign tumor of the pituitary gland. The pathogenesis of most PA is considered as a multifactorial process, that involves genetic mutations, alterations in gene transcription, and epigenetic factors. Their interaction promotes tumorigenesis. The processes ar...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331889/ https://www.ncbi.nlm.nih.gov/pubmed/35892421 http://dx.doi.org/10.3390/brainsci12080980 |
_version_ | 1784758512877830144 |
---|---|
author | Gedvilaite, Greta Vilkeviciute, Alvita Glebauskiene, Brigita Kriauciuniene, Loresa Liutkeviciene, Rasa |
author_facet | Gedvilaite, Greta Vilkeviciute, Alvita Glebauskiene, Brigita Kriauciuniene, Loresa Liutkeviciene, Rasa |
author_sort | Gedvilaite, Greta |
collection | PubMed |
description | Pituitary adenoma (PA) is the most common benign tumor of the pituitary gland. The pathogenesis of most PA is considered as a multifactorial process, that involves genetic mutations, alterations in gene transcription, and epigenetic factors. Their interaction promotes tumorigenesis. The processes are increasingly focused on changes in telomere length. Our study enrolled 126 patients with PA and 368 healthy subjects. DNA samples from peripheral blood leukocytes were purified by the DNA salting-out method. The RT-PCR carried out SNPs and relative leukocyte telomere lengths (RLTL). ELISA determined the level of TEP1 in blood serum. Binary logistic regression revealed that TERC rs35073794 is likely associated with increased odds of PA development and macro-PA development. It is also associated with decreased odds of active PA, non-invasive PA, and PA without relapse development. Also, we discovered that PA patients with at least one G allele of the TEP1 gene polymorphism rs1713418 have lower serum TEP1 levels than healthy individuals (p = 0.035). To conclude, the study revealed that TERC rs35073794 might be a potential biomarker for PA development. |
format | Online Article Text |
id | pubmed-9331889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93318892022-07-29 Molecular Markers of Telomerase Complex for Patients with Pituitary Adenoma Gedvilaite, Greta Vilkeviciute, Alvita Glebauskiene, Brigita Kriauciuniene, Loresa Liutkeviciene, Rasa Brain Sci Article Pituitary adenoma (PA) is the most common benign tumor of the pituitary gland. The pathogenesis of most PA is considered as a multifactorial process, that involves genetic mutations, alterations in gene transcription, and epigenetic factors. Their interaction promotes tumorigenesis. The processes are increasingly focused on changes in telomere length. Our study enrolled 126 patients with PA and 368 healthy subjects. DNA samples from peripheral blood leukocytes were purified by the DNA salting-out method. The RT-PCR carried out SNPs and relative leukocyte telomere lengths (RLTL). ELISA determined the level of TEP1 in blood serum. Binary logistic regression revealed that TERC rs35073794 is likely associated with increased odds of PA development and macro-PA development. It is also associated with decreased odds of active PA, non-invasive PA, and PA without relapse development. Also, we discovered that PA patients with at least one G allele of the TEP1 gene polymorphism rs1713418 have lower serum TEP1 levels than healthy individuals (p = 0.035). To conclude, the study revealed that TERC rs35073794 might be a potential biomarker for PA development. MDPI 2022-07-25 /pmc/articles/PMC9331889/ /pubmed/35892421 http://dx.doi.org/10.3390/brainsci12080980 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gedvilaite, Greta Vilkeviciute, Alvita Glebauskiene, Brigita Kriauciuniene, Loresa Liutkeviciene, Rasa Molecular Markers of Telomerase Complex for Patients with Pituitary Adenoma |
title | Molecular Markers of Telomerase Complex for Patients with Pituitary Adenoma |
title_full | Molecular Markers of Telomerase Complex for Patients with Pituitary Adenoma |
title_fullStr | Molecular Markers of Telomerase Complex for Patients with Pituitary Adenoma |
title_full_unstemmed | Molecular Markers of Telomerase Complex for Patients with Pituitary Adenoma |
title_short | Molecular Markers of Telomerase Complex for Patients with Pituitary Adenoma |
title_sort | molecular markers of telomerase complex for patients with pituitary adenoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331889/ https://www.ncbi.nlm.nih.gov/pubmed/35892421 http://dx.doi.org/10.3390/brainsci12080980 |
work_keys_str_mv | AT gedvilaitegreta molecularmarkersoftelomerasecomplexforpatientswithpituitaryadenoma AT vilkeviciutealvita molecularmarkersoftelomerasecomplexforpatientswithpituitaryadenoma AT glebauskienebrigita molecularmarkersoftelomerasecomplexforpatientswithpituitaryadenoma AT kriauciunieneloresa molecularmarkersoftelomerasecomplexforpatientswithpituitaryadenoma AT liutkevicienerasa molecularmarkersoftelomerasecomplexforpatientswithpituitaryadenoma |